Document Detail


Increasing the sample size when the unblinded interim result is promising.
MedLine Citation:
PMID:  15057876     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Increasing the sample size based on unblinded interim result may inflate the type I error rate and appropriate statistical adjustments may be needed to control the type I error rate at the nominal level. We briefly review the existing approaches which allow early stopping due to futility, or change the test statistic by using different weights, or adjust the critical value for final test, or enforce rules for sample size recalculation. The implication of early stopping due to futility and a simple modification to the weighted Z-statistic approach are discussed. In this paper, we show that increasing the sample size when the unblinded interim result is promising will not inflate the type I error rate and therefore no statistical adjustment is necessary. The unblinded interim result is considered promising if the conditional power is greater than 50 per cent or equivalently, the sample size increment needed to achieve a desired power does not exceed an upper bound. The actual sample size increment may be determined by important factors such as budget, size of the eligible patient population and competition in the market. The 50 per cent-conditional-power approach is extended to a group sequential trial with one interim analysis where a decision may be made at the interim analysis to stop the trial early due to a convincing treatment benefit, or to increase the sample size if the interim result is not as good as expected. The type I error rate will not be inflated if the sample size may be increased only when the conditional power is greater than 50 per cent. If there are two or more interim analyses in a group sequential trial, our simulation study shows that the type I error rate is also well controlled.
Authors:
Y H Joshua Chen; David L DeMets; K K Gordon Lan
Related Documents :
18944756 - Spatial pattern analysis of strawberry leaf blight in perennial production systems.
16817516 - Demonstration and evaluation of a method for assessing mediated moderation.
20515166 - Ironless transducer for measuring the mechanical properties of porous materials.
9449936 - Design of a study to improve accuracy in reading mammograms.
18263546 - Learning capacity and sample complexity on expert networks.
16283536 - Non-linear mixed effects modeling - from methodology and software development to drivin...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Statistics in medicine     Volume:  23     ISSN:  0277-6715     ISO Abbreviation:  Stat Med     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-04-01     Completed Date:  2004-07-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8215016     Medline TA:  Stat Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  1023-38     Citation Subset:  IM    
Copyright Information:
Copyright 2004 John Wiley & Sons, Ltd.
Affiliation:
Merck Research Laboratories, Blue Bell, PA 19422, USA. joshua_chen@merck.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-HIV Agents / therapeutic use
Clinical Trials as Topic / methods*
Computer Simulation
HIV Infections / drug therapy
HIV-1 / immunology
Humans
RNA, Viral / blood
Research Design*
Sample Size*
Grant Support
ID/Acronym/Agency:
R01 CA18332/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/RNA, Viral

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chromosome 17p13.2 transfer reverts transformation phenotypes and Fas-mediated apoptosis in breast e...
Next Document:  Sensitivity analysis of longitudinal normal data with drop-outs.